


What is Angelman syndrome?



Angelman Syndrome

is a genetic disorder of Chromosome 15 affecting a gene called UBE3A resulting in a severe developmental delay



The condition gets its name from the doctor who first described it in 1965 – **Dr Harry Angelman**

What are the features?

Developmental Delay
No or minimal use of words
Movement disorder, Seizures
Sleep Disturbance
Light hair & skin

and remember...

People with AS have great smiles & warm personalities
AS is a Disorder not a disease so individuals can live happy & healthy lives when symptoms such as epilepsy are under control


How common is it?

About
350
people in
IRELAND
have Angelman
syndrome


18
people worldwide
are born with AS
every day

People with
Angelman
syndrome?

Who does it affect?



It affects males & female equally



It is present in all nationalities, races and ethnic groups

Why did it happen?



Chromosome disorder occurred at the point of conception and nothing the mother or father did could have caused it or prevented it from happening

5% cases are inherited

95% cases are completely random



Scientists are researching ways to treat the cognitive, motor and epileptic aspects of AS

Can it be treated?

People with AS benefit from therapies such as Communication, Physiotherapy and Occupational therapy. There are medical treatments to help with epilepsy, nutrition and sleep

Timeline of Angelman Syndrome:

1965

Dr Harry Angelman publishes a report entitled "Puppet Children" about 3 children he observed

1982

Name changed from 'Happy Puppet' to Angelman Syndrome

1997

The cause of AS discovered by Dr. Joseph Wagstaff & Dr. Arthur Beaudet – mutation or deletion of UBE3A gene

2011

Dr Ben Philpot discovers how to "switch on" the silent paternal genetic code on Chromosome 15 in a mouse

The Future

HOPE IS IN OUR GENES!

1980's

Research into AS begins in University of Florida under the direction of Dr Charles Williams

1987

Discovery that absent genetic code on maternal Chromosome 15 is the genetic marker for AS

2007

Neurological deficits can be reversed in a mouse model with AS

2012

Dr Ed Weeber begins clinical trials with 24 children using Minocycline to treat cognition and motor function